Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir

AIDS Research and Human Retroviruses

Volumn 14, Issue 5, 1998, Pages 435-444

  Rossi, Luigia ^a   Brandi, Giorgio ^a   Schiavano, Giuditta F ^a   Balestra, Emanuela ^b   Millo, Enrico ^c   Scarfi, Sonia ^c   Damonte, Gianluca ^c   Gasparini, Anna ^c   Magnani, Mauro ^a   Perno, Carlo Federico ^b   Benatti, Umberto ^c   De Flora, Antonio ^c  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR DERIVATIVE; ANTIVIRUS AGENT; P1 THYMIDINE 3' AZIDO 2',3' DIDEOXYRIBOSIDE 5' P2 GUANINE 9(2 HYDROXYETHOXYMETHYL)PYROPHOSPHATE; UNCLASSIFIED DRUG; ZIDOVUDINE DERIVATIVE;

ARTICLE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; MACROPHAGE ACTIVATION; PHOSPHORYLATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

EID: 17144467334     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.435     Document Type: Article

References (32)

1. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, and Gendelman HC: Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 1990;8:169-194.
2. Wu L, Morahan PS, Hendrzak JA, and Eisenstein TK: Herpes simplex virus type 1 replication and IL-1 beta gene expression in mouse peritoneal macrophages activated in vivo by an attenuated Salmonella typhimurium vaccine or Corynebacterium parvum. Microbiol Pathog 1994;16:387-399.
3. Nikkels AF, Debrus S, Sadzot-Delvaux C, Piette J, Delvenne P, Rentier B, and Pierard GE: Comparative immunohistochemical study of herpes simplex and varicella zoster infections. Virchows Arch A Pathol Anat Histopathol 1993;422:121-126.
4. Minton EJ, Tysoe C, Sinclair JH, and Sissons JG: Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol 1994;68:4017-4021.
5. Golden MP, Kim S, Hammer SM, Ladd EA, Schaffer PA, De Luca N, and Albrecht MA: Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992;166:494-499.
6. Vlach J and Pitha PN: Herpes simplex virus type 1-mediated induction of human immunodeficiency virus type 1 provirus correlates with binding of nuclear proteins to the NF-kappa B enhancer and leader sequence. J Virol 1992;66:3616-3623.
7. Heng MC, Heng SY, and Allen SG: Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343:255-258.
8. Mitsuya H, Yarchoan R, and Broder S: Molecular targets for AIDS therapy. Science 1990;249:1533-1544.
9. Fyfe JA, Kellr PM, Furman PA, et al.: Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2 hydroxyethoxymethyl) guanine. J Biol Chem 1978;253: 8721-8727.
10. Ba-L) replication in fresh and cultured human peripheral blood monocyte/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111-1125.
11. Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, and Piedimonte G: Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies. Proc Natl Acad Sci USA 1992;89:6477-6481.
12. Parker WB and Cheng YC: Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 1994;6:57-61.
13. Lewis W and Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nature Med 1995;1:417-422.
14. Magnani M, Casabianca A, Fraternale A, Brandi G, Gessani S, Williams R, Giovine M, Damonte G, De Flora A, and Benatti U: Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. Proc Natl Acad Sci USA 1996;93:4403-4408.
15. Hostetler KY, Stuhmiller LM, Lenting BM, van den Bosch H, and Richman DD: Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J Biol Chem 1990;265:6112-6117.
16. Yoshikawa M, Kato T, and Takenishi T: A novel method for phosphorylation of nucleosides to 5′-nucleotides. Tetrahedron Lett 1967;50:5065-5068.
17. van Wijk GMT, Hostetler KY, and van den Bosch H: Antiviral nucleoside diphosphate diglycerides: Improved synthesis and facilitated purification. J Lipid Res 1992;33:1211-1219.
18. Magnani M, Rossi L, Bianchi M, Cucchiarini L, and Stocchi V: Reversed-phase liquid chromatographic determination of 2′,3′-dideoxycytidine in human blood samples. J Chromatogr BA 1989;491:215-220.
19. Piedimonte G, Montroni M, Silvestri G, Silvotti L, Donatini A, Rossi L, Borghetti AF, and Magnani M: Phagocytosis reduces HIV-1 production in human monocyte/macrophages infected in vitro. Arch Virol 1993;130:463-469.
20. Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, Baba M, Johns DG, and De Clercq E: Marked in vivo anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-336.
21. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, and Maudgai PC: A novel selective broad-spectrum anti-DNA virus agent. Nature (London) 1986;323:464-467.
22. Perno C-F, Balestra E, Aquaro S, Panti S, Cenci A, Lazzarino G, Tavazzi B, Di Pierro D, Balzarini J, and Caliò R: Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-Phosphonylmethoxyethyl) adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol Pharmacol 1996;50:359-365.
23. Balzarini J, Hao Z, Herdewijn P, Johns DG, and De Clercq E: Intracellular metabolism and mechanism of anti-retrovirus action of 9(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991;88:1499-1503.
24. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature (London) 1997;387:188-191.
25. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1997;387:183-188.
26. Rossi L, Brandi G, Fraternale A, Schiavano GF, Chiarantini L, and Magnani M: Inhibition of murine retrovirus-induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′-triphosphate. J AIDS 1993;6:1179-1186.
27. Zocchi E, Guida L, Franco L, Silvestro L, Guerrini M, Benatti U, and De Flora A: Free ADP-ribose in human erythrocytes: Pathways of intra-erythrocytic conversion and non-enzymic binding to membrane proteins. Biochem J 1993;295:121-130.
28. Knipe DM: The role of viral and cellular nuclear protein in herpes simplex virus replication. In: Advances in Virus Research (Maramorasch K, et al., eds.). Academic Press, San Diego, California, 1989, pp. 85-123.
29. Crumpacker CS, Schnipper LE, Marlowe SI, et al.: Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982;306:343-346.
30. Erlich KS, Mills J, Chatis P, et al.: Acyclovir-resistant herpes simplex virus infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-296.
31. Darby G and Filed HJ: Alterated substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature (London) 1981;289:81-83.
32. Balfour HH: Resistance of herpes simplex to acyclovir. Ann Intern Med 1983;98:404-406.